<p>Comparison of the incidence of PN in patients treated with IV and SC bortezomib in the IFM trial and CMG analysis.</p
Background: Recent studies have demonstrated synergy between bortezomib and a number of conventional...
Comparison of clinicopathological parameters between patients with and without RAI-avid mLN in the l...
Bortezomib, a first generation proteasome inhibitor, is used in both newly diagnosed and relapsed my...
<p>Comparison of incidence of LNM between matched NACT group and PST group, primary NACT group with ...
Bortezomib is a first-in-class proteasome inhibitor, approved for the treatment of multiple myeloma....
<p>Odds ratio of all-grade and high-grade cardiotoxicity associated with bortezomib vs. control.</p
<p>The incidence of sBBC and mBBC compared with that of UBC among patients diagnosed between June 20...
textabstractBortezomib-dexamethasone is widely used for relapsed myeloma in routine clinical practic...
<p>Comparison of incidence and distribution of LNM between the matched NACT and PST group (A-B), cli...
<p>Illustration of the negative validation of the approach in a data set from156 relapsed MM patient...
This subgroup analysis of the phase III APEX (Assessment of Proteasome Inhibition for Extending Remi...
Comparison of clinicopathological parameters between patients with and without RAI-avid mLN in the i...
S exposed only to vehicle at various doses of bortezomib, POH, or combination of both for 24 hours. ...
A propensity score-matched analysis compared bortezomib, melphalan, and prednisolone (VMP) in the AL...
The comparison of Kaplan-Meier survival curves for MICs of drugs used against NTM.</p
Background: Recent studies have demonstrated synergy between bortezomib and a number of conventional...
Comparison of clinicopathological parameters between patients with and without RAI-avid mLN in the l...
Bortezomib, a first generation proteasome inhibitor, is used in both newly diagnosed and relapsed my...
<p>Comparison of incidence of LNM between matched NACT group and PST group, primary NACT group with ...
Bortezomib is a first-in-class proteasome inhibitor, approved for the treatment of multiple myeloma....
<p>Odds ratio of all-grade and high-grade cardiotoxicity associated with bortezomib vs. control.</p
<p>The incidence of sBBC and mBBC compared with that of UBC among patients diagnosed between June 20...
textabstractBortezomib-dexamethasone is widely used for relapsed myeloma in routine clinical practic...
<p>Comparison of incidence and distribution of LNM between the matched NACT and PST group (A-B), cli...
<p>Illustration of the negative validation of the approach in a data set from156 relapsed MM patient...
This subgroup analysis of the phase III APEX (Assessment of Proteasome Inhibition for Extending Remi...
Comparison of clinicopathological parameters between patients with and without RAI-avid mLN in the i...
S exposed only to vehicle at various doses of bortezomib, POH, or combination of both for 24 hours. ...
A propensity score-matched analysis compared bortezomib, melphalan, and prednisolone (VMP) in the AL...
The comparison of Kaplan-Meier survival curves for MICs of drugs used against NTM.</p
Background: Recent studies have demonstrated synergy between bortezomib and a number of conventional...
Comparison of clinicopathological parameters between patients with and without RAI-avid mLN in the l...
Bortezomib, a first generation proteasome inhibitor, is used in both newly diagnosed and relapsed my...